Long-term safety and efficacy of the combination of belimumab and rituximab in the treatment of severe and refractory SLE: a preliminary report
Long-lasting remission was observed in patients with SLE following combination treatment with rituximab and belimumab. We observed no significant hypogammaglobulinaemia and, notably, persistent reduction of DN B cells.
Authors
- Sascha C. A. T. Verbruggen (ORCID: https://orcid.org/0000-0003-4866-9865)
- Marjolein J.A.L. Wetzels (ORCID: https://orcid.org/0000-0003-2501-3230)
- Robbert J Goekoop
- Ton J. Rabelink (ORCID: https://orcid.org/0000-0001-6780-5186)
- Eline J. Arends (ORCID: https://orcid.org/0000-0003-4619-4077)
- T. Huizinga (ORCID: https://orcid.org/0000-0001-7033-7520)
- Sandra W. van der Kooij
- Tineke Kraaij (ORCID: https://orcid.org/0000-0002-0874-3365)
- Cees van Kooten (ORCID: https://orcid.org/0000-0002-6257-0899)
- Y K Onno Teng (ORCID: https://orcid.org/0000-0001-9920-2195)
- Mieke van Schaik (ORCID: https://orcid.org/0000-0003-3823-4702)
- Sylvia W.A. Kamerling
Institutions
- Leiden University Medical Center (NL)
- Haga Hospital (NL)
Publication Details
- Journal
- Lupus Science & Medicine
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1136/lupus-2024-001424
- Citations
- 8
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 13.34
Funders
- Nierstichting